Results 131 to 140 of about 11,732 (171)

Early kinetics of CA19-9 and CEA after 5-FU-based chemotherapy for gastrointestinal cancers. [PDF]

Discov Oncol
Lange S, Wenzel P, Winter C, Ruland J, Schmid RM, Algül H, Quante M, Friedrich M.   +7 more
europepmc   +1 more source

Impact of Tumor Genomic Profile on Adjuvant Chemotherapy Efficacy in Resected Pancreatic Adenocarcinoma: Results From the PRODIGE-24/CCTG PA6 Study. [PDF]

J Clin Oncol
Witz A, Conroy T, Lambert A, Salleron J, Diallo A, Husson M, Nicolle R, Hammel P, Biagi J, Renouf DJ, Turpin A, Richard C, Bachet JB, Iovanna J, Dusetti N, Monard L, Mauduit M, Cros J, Harlé A.   +18 more
europepmc   +1 more source

Adjuvant Therapy in Pancreatic Ductal Adenocarcinoma-Past, Present, and Future. [PDF]

Cancers (Basel)
Tran A, Jain T, Fei N, Dudeja V.
europepmc   +1 more source

Real-world retrospective cohort study of three conversion therapy regimens for unresectable locally advanced pancreatic cancer: a single-center 5-year analysis focused on conversion resection rate and survival outcomes. [PDF]

Transl Cancer Res
He RZ, Zhou M, Chen YJ, Guo XJ.
europepmc   +1 more source

Healthcare resource utilization and economic burden of metastatic pancreatic cancer: a US commercial and Medicare claims analysis. [PDF]

Future Oncol
Fuldeore R, Amaefule AQ, Georgieva G, Kimura T, Jiang B, Yu KH.   +5 more
europepmc   +1 more source

Capecitabine-Induced Hand-Foot Syndrome With Genital Involvement. [PDF]

J Adv Pract Oncol
Feng Y, Baroody C, Al Mutar S.
europepmc   +1 more source

Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma-UK Tertiary Cancer Centre Experience. [PDF]

Cancers (Basel)
Yeung KTD, Gomberg S, Hodgson W, Jefferies P, Cunningham D, Rao S, Chau I, Starling N, Fribbens C, Athauda A, Tait D, Chong I, Hunt A, Dillon MT, Kumar S, Jiao LR, Bhogal RH, Aitken K.   +17 more
europepmc   +1 more source

The 30% reduction of baseline CA19-9 could stratify the prognosis of advanced pancreatic ductal adenocarcinoma with RECIST stable disease after first-line chemotherapy. [PDF]

BMC Cancer
Zhang X, Huang XT, Fu AQ, Huang CS, Xu QC, Lai JM, Liang LJ, Yin XY.   +7 more
europepmc   +1 more source

Developing a Histology-Based Artificial Intelligence Biomarker to Predict Adjuvant Chemotherapy Benefit in Pancreatic Cancer. [PDF]

J Clin Oncol
Beaufils A, De Martino J, Jiang X, Blanchard T, Fraunhoffer N, Mendes D, Pignolet C, Bourega T, Meneghetti AR, Sainath S, Albuquerque M, Colnot N, Tihy M, Turpin A, Ben Abdelghani M, Wei A, Mitry E, Lecomte T, Biagi J, Artru P, Evesque L, Lambert A, Renouf DJ, Mauduit M, Dusetti NJ, Hammel P, Conroy T, Bachet JB, de Mestier L, Rebours V, Cros J, Kather JN, Nicolle R.   +32 more
europepmc   +1 more source

Outcomes of Irreversible Electroporation for Treatment of Refractory Locally Advanced Pancreatic Cancer. [PDF]

J Vasc Interv Radiol
Azevedo R, Imagawa D, Rara M, Cho H, Cho K, Valerin J, Lee FC, Dayyani F, Fernando D, Abi-Jaoudeh N.   +9 more
europepmc   +1 more source